--- title: "如瑞迪博士在印度推出了针对 2 型糖尿病患者的口服药物 Obeda" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/287073753.md" description: "药明康德推出了 Obeda，一种用于 2 型糖尿病患者的口服赛美特肽生物仿制药，已在印度上市。这种每日一次的药片旨在改善血糖控制，并在此之前推出了赛美特肽的注射剂。印度中央药品标准控制组织（CDSCO）在一项 III 期研究显示其疗效和安全性与创新药物相当后批准了 Obeda。该药品提供三种剂量，价格从每片 99 卢比到 225 卢比不等。首席执行官 M V Ramana 强调了对印度糖尿病护理质量和供应可靠性的承诺" datetime: "2026-05-20T05:18:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287073753.md) - [en](https://longbridge.com/en/news/287073753.md) - [zh-HK](https://longbridge.com/zh-HK/news/287073753.md) --- # 如瑞迪博士在印度推出了针对 2 型糖尿病患者的口服药物 Obeda Dr. Reddy’s Laboratories has announced the commercial launch of its oral semaglutide biosimilar under the brand name Obeda in India. The once-daily prescription tablet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults living with type 2 diabetes mellitus. The launch follows the company’s recent introduction of generic semaglutide injections in India and Canada, expanding its portfolio of glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies. According to data cited from the ICMR-INDIAB study, India faces a significant metabolic disease burden, with more than 101 million adults diagnosed with diabetes, an 11.4 per cent prevalence rate, and approximately 136 million individuals classified as prediabetic. The Central Drugs Standard Control Organisation (CDSCO) granted marketing approval for Obeda following a review of data from a Phase III clinical study conducted in India. The trial enrolled 288 participants with type 2 diabetes. According to the company’s regulatory filing, the clinical study demonstrated non-inferior efficacy and a comparable safety profile to the innovator oral drug. The trial measured parameters including fasting and post-prandial plasma glucose, weight reduction, and the proportion of participants achieving an HbA1c level below 7 per cent at 12 and 24 weeks. Additionally, the study reported that no anti-drug antibodies were detected, indicating an immunogenicity profile comparable to the reference product. Obeda is formulated using a recombinant DNA (rDNA)-origin active pharmaceutical ingredient (API), developed and manufactured in-house by Dr. Reddy’s. The medication is available in three distinct strengths to allow flexible dosing, with pricing structured by dosage. The lowest strength, 3 mg, is priced at Rs 99 per tablet. The mid-range 7 mg dose is available at Rs 135 per tablet, while the highest strength of 14 mg is priced at Rs 225 per tablet. “The launch of our oral semaglutide for patients with diabetes marks an important step in our journey to broaden access to advanced diabetes care,” said M V Ramana, chief executive officer, Global Generics, at Dr. Reddy’s. “As the product is developed and formulated in-house, we are committed to reliable supply and consistent quality for patients in India.” The company stated that the in-house manufacturing structure is designed to secure supply-chain reliability for the chronic metabolic disease market in India and potentially other emerging regions. As a prescription-only medication, patients are advised to consult medical professionals regarding treatment regimens. ### 相关股票 - [RDY.US](https://longbridge.com/zh-CN/quote/RDY.US.md) ## 相关资讯与研究 - [无糖可乐与零度可乐爱好者之间的激烈派系之争](https://longbridge.com/zh-CN/news/287047235.md) - [礼来 orforglipron 可帮助停止 GLP-1 注射剂的人群维持体重减轻效果](https://longbridge.com/zh-CN/news/286423020.md) - [Adv Sci：复旦大学蒋伟等团队发现二甲双胍可致其依赖 UXS1，靶向抑制可协同杀伤](https://longbridge.com/zh-CN/news/286858232.md) - [强生重症肌无力治疗新药获国家药监局批准上市](https://longbridge.com/zh-CN/news/287196062.md) - [全球并购 “向东看”！小摩投行主席：从生物医药到前沿科技，资本正重新审视中国创新价值](https://longbridge.com/zh-CN/news/287209539.md)